The Latest Cardiac and Vascular News
THOUSAND OAKS, Calif., Aug. 4, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2022. Key results include: Total revenues increased 1% to $6.6 billion in comparison to the second quarter of 2021, resulting from 3% growth in global […]
Study Showed Significant, Sustained Reduction in Lipoprotein(a) During Treatment Period Lipoprotein(a) Reduction was Consistent With Phase 1 Results THOUSAND OAKS, Calif., May 31, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced positive topline data from the Phase 2 OCEAN(a)-DOSE clinical study, evaluating olpasiran […]
Studies Showed Sustained Reduction in LDL-C With no new Safety Findings The Combined Studies Evaluated Safety and Tolerability of Repatha in More Than 6,600 Patients for Over Five Years After Completing the Phase 3 FOURIER Trial Repatha is the Longest […]
THOUSAND OAKS, Calif., Feb. 7, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2021 versus comparable periods in 2020. Key results include: For the fourth quarter, total revenues increased 3% to $6.8 billion in comparison to […]
THOUSAND OAKS, Calif., Nov. 2, 2021 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2021. Key results include: Total revenues increased 4% to $6.7 billion in comparison to the third quarter of 2020, driven by higher unit demand, partially offset […]
Final Analysis From Open-Label Extension Study in Patients with Human Immunodeficiency Virus and Dyslipidemia THOUSAND OAKS, Calif., May 11, 2021 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the presentation of four cardiovascular research abstracts, including final data from the Repatha® (evolocumab) open label extension […]
Breakthrough Multicentered Study will Evaluate Efficacy of Digital Health Data Collection Outside the Clinic for Guideline-Directed Heart Failure Therapy NEW YORK, April 13, 2021 /PRNewswire/ — Datos Health, a leader in remote care automation, today announced its collaboration with Amgen, one of the world’s […]
THOUSAND OAKS, Calif., Feb. 2, 2021 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2020 versus comparable periods in 2019. Key results include: For the fourth quarter, total revenues increased 7% to $6.6 billion in comparison to the […]
THOUSAND OAKS, Calif., Nov. 23, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the Company has provided notice to Cytokinetics of termination of its collaboration and its intention to transition the development and commercialization rights for omecamtiv mecarbil and AMG 594. Omecamtiv mecarbil, […]
THOUSAND OAKS, Calif., Oct. 28, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2020. Key results include: Total revenues increased 12% to $6.4 billion in comparison to the third quarter of 2019 driven by higher volume growth, partially […]
